References
- Academy of Managed Care Pharmacy. Format for formulary submissions (2000).
- Sullivan SD, Lyles A, Luce B, Grigar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. JMCP 7 (4), 272–282 (2001).
- Gross R, Strom BL. Toward improved adverse event/suspected adverse drug reaction reporting. Pharmacoepidemiol. Drug Safety 12 (2), 89–91 (2003).
- Mather DB, Sullivan SD, Augenstein D, Fullerton DSP, Atherly D. Incorporating clinical outcomes and economic consequences into drug formulary decisions; a practical approach. AJMC5 (3), 277–285 (1999).
- Lilienfeld D, Stolley P Foundations of Epidemiology Third Edition. Oxford University Press, NY, USA (1994).
- Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin. Ther. 2(6), 1194–1202 (1998).
- Mauskopf J. Why study pharmacoeconomics? Expert Rev Pharmacoeconomics Outcomes Res.1 (1), 1–3 (2001).
- Shaya FT, Mullins CD, Wong W Incidence or prevalence: implications for formulary decision-making. Proceedings of the Seventh Annual Meeting, International Society for Pharmacoeconomics and Outcomes Research. VA, USA (2002).
- Shaya FT, Mullins CD, Wong W Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoeconomics Outcomes Res. 2(5), 89–96 (2002).
- Hodgson TA, Meiner MR. Cost-of-illness methodology: a guide to current practices and procedures. Millbank Mem. Fund Q. Health Soc. 60(3), 429–462 (1982).
- Rice DP, Cooper BS. The economic value of human life. Am. J Pub. Health 57, 1954–1966 (1967).